The global nuclear medicines market is
expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of
around 12.29% from 2015 to 2021. Nuclear medicine utilizes the radioisotope for
application in diagnosis and treatment of diseases. The drugs containing
radionuclides are called radiopharmaceuticals. The uses in radiological imaging
include Magnetic Resonance Imaging (MRI), Computerized tomography (CT),
Positron Emission Tomography (PET) and Single Proton Emission Tomography
(SPECT).
Get More Information of Global Nuclear Medicine Market Report @ http://www.orbisresearch.com/reports/index/global-nuclear-medicine-market-growth-trends-and-forecasts-2017-2022 .
The use of nuclear medicines for diagnostic
purposes has gained huge popularity all around the world. There has been
increased use of SPECT, PET, CT, and MRI for diagnosis of cardiac diseases,
brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic
purposes for treatment of Alzheimerdisease, coronary heart diseases, bone
metastasis, cancers and different medical conditions affecting the thyroid
gland, and scar tissue removal. Advancement in diagnostic imaging is bringing
in more use of nuclear medicine. Nuclear cardiology has gained great popularity
in North America.
Global Nuclear Medicines Market- Market
Dynamics
The report lists several driving and
restraining factors for the global nuclear medicines market. In addition, it
sheds light on several opportunities that exist for the market players. Some of
these are listed below.
Purchase a copy of Global Nuclear Medicine Market visit @ http://www.orbisresearch.com/contact/purchase/219337 For more information contact sales@orbisresearch.com .
Drivers
Increasing incidence and prevalence of cancer and cardiac ailments
Increasing application of SPECT and PET with advancement of technology
Growing awareness amongst physicians
Public awareness for better healthcare
Restraints
Short half-life of radiopharmaceuticals
High capital investment required for development
Stringent regulatory guidelines
Opportunities
Increasing imaging technologies
Potential radioisotopes in pipeline
Increasing neurological applications and cyclotron based production
Increasing incidence and prevalence of cancer and cardiac ailments
Increasing application of SPECT and PET with advancement of technology
Growing awareness amongst physicians
Public awareness for better healthcare
Restraints
Short half-life of radiopharmaceuticals
High capital investment required for development
Stringent regulatory guidelines
Opportunities
Increasing imaging technologies
Potential radioisotopes in pipeline
Increasing neurological applications and cyclotron based production
The global nuclear medicine market has been
segmented based on type, application, and geography.
Based on the type of product, the market has been segmented into the diagnostic market and therapeutic market, wherein the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes (subdivided intoRubidium-82, Flourine-18).
Based on the type of product, the market has been segmented into the diagnostic market and therapeutic market, wherein the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes (subdivided intoRubidium-82, Flourine-18).
The therapeutics category has been segmented
into Alpha emitters (Radium-223), Beta Emitters (includes Iodine-131,
Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125,
Cesium-131, Palladium-103, & Iridium-192).
The segmentation based on the application has
been similarly subdivided based on diagnostic and therapeutic application. The
diagnostic application includes the application of SPECT and PET in cardiology,
neurology, oncology and others. The therapeutic applications include
application in oncology, thyroid, endocrinology and various other therapeutic
areas.
The global nuclear medicine market has been
geographically segmented into North America (includes United States, Canada,
and Mexico), Europe (includes Germany, UK, France, Italy Spain, Russia and
Others), Asia-Pacific (includes China, Japan, India, Australia South Korea and
Others), Middle East and Africa (includes UAE, Saudi Arabia, Israel, and others),
and Latin America (includes Brazil, Argentina, Mexico, and others). Due to high
technological advancement coupled with a developed economy, North America has
the largest market share, followed by Europe and Asia-Pacific.
Currently, the segment of diagnostics holds the largest share in nuclear medicines market, where SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.
Currently, the segment of diagnostics holds the largest share in nuclear medicines market, where SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.
Some of the key players in the market are:
Bracco Imaging S.P.A.
BRACCO PHARMA
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary of General Electric Company)
Nordion, Inc.
Taiyo Nippon Sanso Corporation
Bracco Imaging S.P.A.
BRACCO PHARMA
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary of General Electric Company)
Nordion, Inc.
Taiyo Nippon Sanso Corporation
What the Report Offers
Market definition for the nuclear medicines market along with identification of key drivers and restraints for the market.
Market analysis for the nuclear medicines market, with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Market definition for the nuclear medicines market along with identification of key drivers and restraints for the market.
Market analysis for the nuclear medicines market, with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape
section with profiles of major companies along with their strategic initiatives
and market share.
Identification and analysis of the macro and micro factors that affect the nuclear medicines market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the nuclear medicines market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Some Points From Toc:
1. INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 MARKETS COVERED
1.3 MAJOR STAKEHOLDERS
1.4 RESEARCH METHODOLOGY
1.1 REPORT DESCRIPTION
1.2 MARKETS COVERED
1.3 MAJOR STAKEHOLDERS
1.4 RESEARCH METHODOLOGY
2 EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 Market Drivers
3.1.1 Increasing Incidents of Cancer and Cardiac Ailments
3.1.2 Increasing SPECT AND PET applications
3.1.3 Growing Public Awareness for healthcare
3.2 MARKET CONSTRAINTS
3.2.1 Short Half-life of Radiopharmaceuticals
3.2.2 High Capital Investment
3.2.3 Regulatory Guidelines
3.2.4 Reimbursement
3.3 OPPORTUNITIES
3.3.1 Increasing Imaging Technologies
3.3.2 Potential Radioisotopes in Pipeline
3.3.3 Increasing Neurological Applications
3.3.4 Cyclotron based production
3.4 THREATS
3.4.1 Shutdown of Nuclear Reactors
3.1 Market Drivers
3.1.1 Increasing Incidents of Cancer and Cardiac Ailments
3.1.2 Increasing SPECT AND PET applications
3.1.3 Growing Public Awareness for healthcare
3.2 MARKET CONSTRAINTS
3.2.1 Short Half-life of Radiopharmaceuticals
3.2.2 High Capital Investment
3.2.3 Regulatory Guidelines
3.2.4 Reimbursement
3.3 OPPORTUNITIES
3.3.1 Increasing Imaging Technologies
3.3.2 Potential Radioisotopes in Pipeline
3.3.3 Increasing Neurological Applications
3.3.4 Cyclotron based production
3.4 THREATS
3.4.1 Shutdown of Nuclear Reactors
About Us:
Orbis Research (orbisresearch.com) is a
single point aid for all your market research requirements. We have vast
database of reports from the leading publishers and authors across the globe.
We specialize in delivering customized reports as per the requirements of our
clients. We have complete information about our publishers and hence are sure
about the accuracy of the industries and verticals of their specialization.
This helps our clients to map their needs and we produce the perfect required
market research study for our clients.
Contact
Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1
(214) 884-6817; +9164101019
No comments:
Post a Comment